476P - Meta-analysis of randomised clinical trials comparing erlotinib alone with erlotinib plus chemotherapy in patients with advanced non–small cell lun...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Non-Small-Cell Lung Cancer, Metastatic
Presenter Chao Chen
Citation Annals of Oncology (2016) 27 (suppl_9): ix139-ix156. 10.1093/annonc/mdw594
Authors C. Chen, H. Hua, X. Gong
  • Bayi Hospital Affiliated Nanjing University Of Chinese Medicine, Nanjing Bayi Hospital, 210001 - Nanjing/CN



To determine whether the use of Erlotinib plus chemotherapy is more effective than the use of Erlotinib alone in patients with advanced non–small cell lung cancer.


A computer-based search was performed. Randomised trials comparing Erlotinib alone with Erlotinib plus chemotherapy as therapy for advanced non–small cell lung cancer were included in this meta-analysis. The primary outcome of interest for our analysis was survival (progression-free survival, and overall survival).


Four trials with 485 patients were eligible for this meta-analysis. Our pooled results suggest that Erlotinib plus chemotherapy is associated with a significant advantage in PFS (HR = 0.51; 95% CI = 0.32–0.81, p = 0.004), but not in OS (HR = 1.03; 95% CI = 0.73-1.32, p = 0.92).


Our analysis indicated that Erlotinib plus chemotherapy could improve the PFS compared to Erlotinib alone as therapy for patients with advanced non–small cell lung cancer. Further study is needed to determine whether Erlotinib plus chemotherapy can produce clinical benefits in selected genetic or molecular subgroups of advanced non–small cell lung cancer.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.